Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - HC Wainwright reduced their Q2 2025 earnings estimates for OPKO Health in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.10) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.34) EPS.

Several other research analysts also recently weighed in on OPK. Barrington Research reissued an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Thursday, May 1st. StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday. Finally, JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a report on Friday, April 25th. They set a "neutral" rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, OPKO Health currently has a consensus rating of "Hold" and a consensus price target of $2.75.

OPKO Health Price Performance

OPK stock traded down $0.01 during trading hours on Monday, hitting $1.25. 705,388 shares of the stock traded hands, compared to its average volume of 3,872,224. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market cap of $991.32 million, a P/E ratio of -6.58 and a beta of 1.42. OPKO Health has a one year low of $1.19 and a one year high of $2.04. The stock has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $1.56.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.12) EPS.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 67,434 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the acquisition, the chief executive officer now owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. This represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders purchased 767,434 shares of company stock valued at $1,238,312. Insiders own 49.69% of the company's stock.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Oak Thistle LLC bought a new stake in shares of OPKO Health during the first quarter worth approximately $26,000. Cerity Partners LLC acquired a new position in shares of OPKO Health in the first quarter valued at about $36,000. Pallas Capital Advisors LLC bought a new position in OPKO Health during the first quarter worth about $43,000. Wealth Enhancement Advisory Services LLC raised its stake in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 12,417 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in OPKO Health during the fourth quarter worth approximately $45,000. Institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.